SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Inspyr Therapeutics Inc. (NSPX)

NSPX RSS Feed
Add NSPX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 9/1/2016 12:10:22 PM - Followers: 38 - Board type: Free - Posts Today: 0




2511 N Loop 1604 W
Suite 204
San Antonio, TX 78258
Phone: 210-479-8112
Email: info@genspera.com

Website: http://www.genspera.com

Craig Dionne President, CEO, CFO
Russell Richerson COO, Secretary
 


Shares Outstanding 27,392,100 a/o Mar 09, 2014
Float Not Available
Authorized Shares 80,000,000 a/o Jun 30, 2009

Latest Report Mar 31, 2014 10-Q
CIK 0001421204
Fiscal Year End 12/31
 

About GenSpera

GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

Business Description

We are a biotechnology company focused on the discovery and development of pro-drug cancer therapeutics, an emerging medical science. A pro-drug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. We were incorporated as a Delaware corporation in 2003.

GenSpera Inc. (GenSpera) is a development-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors including prostate, liver, brain and other cancers. A prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. The Company has four prodrug candidates: G-202, G-114, G-115 and G-301. The Company's primary focus is the clinical development of its compound, G-202, a therapeutic agent with a mechanism of action. G-202 is in Phase II Clinical Trial. G-114 is validated efficacy in pre-clinical animal models. Pilot toxicology is completed for G-115. G-301 is validated efficacy in pre-clinical animal models. The Company is also conducting a Phase II clinical trial to test the utility of G-202 in patients with hepatocellular carcinoma (liver cancer). As of March 27, 2013, it treated one patient in this Phase II trial.


GenSpera harnesses a novel biomedical technology platform to deliver a powerful toxin directly to tumors

  • Phase II clinical trials for lead compound, G-202, are underway in two indications:
    • Hepatocellular carcinoma, or liver cancer
    • Glioblastoma, or brain cancer
  • Experienced and motivated team drives the process:
    • Core team has extensive experience in successfully identifying and bringing oncology treatments to the clinic.
    • Scientific Advisory Board is comprised of leading researchers who are both the inventors of the technology and shareholders.
  • Technology platform supports the development of a suite of drugs targeted at different cancers, as well as other applications such as imaging.
  • Over 15 years of research at Johns Hopkins Medical Center and other renowned research centers, including the University of Copenhagen.
    • Strong intellectual property portfolio
    • No milestones or royalty payments owed to third parties.
  • Leverage the team's passion and expertise in identifying promising treatments and bringing them to the clinic.




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NSPX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
GNSZ News: Current Report Filing (8-k) 08/05/2016 12:19:31 PM
GNSZ News: Notice of Effectiveness (effect) 07/26/2016 06:01:42 AM
GNSZ News: Current Report Filing (8-k) 07/20/2016 09:33:32 AM
GNSZ News: Post-effective Amendment to Registration Statement (pos Am) 07/19/2016 10:52:43 AM
GNSZ News: Statement of Changes in Beneficial Ownership (4) 07/14/2016 04:16:20 PM
PostSubject
#817   What happen? 8 cents willlbone 09/01/16 12:10:21 PM
#816   Genspera Inc., GNSZ, changed to Inspyr Therapeutics Inc., Renee 08/01/16 06:25:12 PM
#815   Much smaller loss than expected on financials. Runners123 05/29/16 11:23:56 AM
#814   Took a 15% loss on this last month. ACWprime 04/12/16 10:09:54 AM
#813   Looks like the answer is NO! duderaja 03/21/16 11:13:39 AM
#812   . 123tom 01/08/16 10:53:24 PM
#811   Bought a few GNSZ lottery tickets today. ACWprime 01/07/16 12:15:17 PM
#810   This cash should get them through one more ACWprime 12/23/15 06:18:05 PM
#809   GENSPERA ANNOUNCES PRIVATE PLACEMENT OF $2.5 MILLION DECEMBER 23, ThesT 12/23/15 03:43:42 PM
#808   up and back down..... 123tom 12/11/15 02:24:44 PM
#807   12x daily volume and not noon yet. duderaja 12/07/15 11:09:33 AM
#806   Up .05 in the last 15 minutes today duderaja 11/16/15 06:30:17 PM
#805   You got fleeced on this one. scottsmith 11/06/15 06:33:36 PM
#804   Harry...Ive been keeping an eye on GNSZ...I actually 123tom 11/06/15 02:25:01 PM
#803   http://www.genspera.com/news/press-releases/detail/612/world-renowned-neuro TomP1 10/30/15 09:58:25 AM
#802   Tom, can you please create an updated chart SquirtyHarry 10/28/15 10:02:36 AM
#801   Poor little baby..... 123tom 10/27/15 06:01:57 PM
#800   Wow, 10 AM and 607 shares traded. Is duderaja 10/22/15 09:58:50 AM
#799   thank you for your response lets hope for SquirtyHarry 10/20/15 04:10:01 PM
#798   harry,the targets are in play....it can take time...nothing 123tom 10/20/15 02:20:25 PM
#797   123tom do you still think we will push SquirtyHarry 10/20/15 01:05:13 PM
#796   Chairman looks confident in this video SquirtyHarry 10/19/15 08:33:54 AM
#795   GNSZ appears to be getting up off 123tom 10/15/15 11:33:10 AM
#794   Have you looked at GBSN? duderaja 10/12/15 09:27:36 AM
#793   yes, that little/big plunge to 24....it looks like 123tom 10/11/15 06:58:58 PM
#792   All I can say is I wish I duderaja 10/10/15 10:42:11 AM
#791   Massive collapse and a good bounce... 123tom 10/09/15 07:25:24 PM
#790   Going to zero? jaytea 10/09/15 10:38:48 AM
#789   ...and target at 35 cents gets hit today. 123tom 10/01/15 10:05:48 PM
#788   GNSZ chart price action today...predictable 123tom 09/25/15 03:06:26 PM
#787   GNSZ....... http://content.screencast.com/users/tabtom123/folders/Jing/media/0aec5990-0cca 123tom 09/24/15 08:20:52 PM
#786   I am. Prana1 09/23/15 01:47:40 PM
#785   Who the heck is buying this POS Mystock76 09/23/15 12:22:25 PM
#784   Why am I still holding this POS? canderson 09/23/15 11:23:16 AM
#783   Selling finally drying up...buyers paying at the ask. ashy2classy 09/18/15 11:26:59 AM
#782   Where has the money come from to run ACWprime 09/17/15 11:58:53 AM
#781   Pretty clear this is just getting hammered so ashy2classy 09/17/15 11:18:07 AM
#780   With the constant selling at the bid we're ashy2classy 09/16/15 02:36:23 PM
#779   This thing created new 52- week low today Rogerthat1 09/16/15 02:14:32 PM
#778   I knew i should have cut my losses canderson 09/16/15 09:58:06 AM
#775   Well it bounced back into the 50's ok....but 123tom 09/15/15 06:07:14 PM
#774   Good call..... bradrad 09/15/15 06:04:50 PM
#773   Price will keeping dropping until they find some partner/money. willlbone 09/15/15 10:10:08 AM
#772   Nonstop selling on any pop. What a POS... ashy2classy 09/15/15 09:51:39 AM
#771   Thanks amigo. Certainly interesting at these levels. scottsmith 09/14/15 05:50:05 PM
#770   I don't think anyone would argue that this ThesT 09/14/15 05:42:53 PM
#769   Tell me more....please. scottsmith 09/14/15 05:13:15 PM
#768   yes,I have to hold here...but might have to 123tom 09/14/15 04:51:17 PM
#767   I agree Impailer 09/14/15 04:31:52 PM
#766   I still think a deal is being struck ThesT 09/14/15 04:29:48 PM
PostSubject